![]()
|
|
||||||||
J. Biol. Chem., Vol. 283, Issue 28, 19636-19645, July 11, 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


¶1
From the
Institut de Recherches Cliniques de Montréal and ¶Department for Microbiology and Immunology, University of Montreal, Montréal, Quebec H2W 1R7, Canada and
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
The U2 auxiliary factor (U2AF) is an integral part of the spliceosome that is important for the recognition of the 3' splice site. U2AF consists of a large and a small subunit, the prototypes of which are U2AF65 and U2AF35. Recent evidence suggests that several homologs of both U2AF subunits exist that are able to regulate alternative splicing. Here we have investigated the expression, intracellular localization, and nucleo-cytoplasmic shuttling of one homolog of the small U2AF subunit, U2AF26, and a splice variant lacking exon 7, U2AF26
E7. In contrast to the nuclear U2AF26, which displays active nucleo-cytoplasmic shuttling, U2AF26
E7 is localized in the cytoplasm. Our studies reveal a nuclear localization sequence in the C-terminal exons 7 and 8 of U2AF26 that differs from the known nuclear localization sequence in U2AF35. In addition, we could identify P32 as a protein that is able to interact with U2AF26 through this domain, and we demonstrate that this interaction is required for the nuclear translocation of U2AF26. Our results suggest the existence of two distinct nuclear import pathways for U2AF26 and U2AF35 that could independently control their intracellular distribution and availability to the splicing machinery. Such a mechanism could work in addition to the differential expression of U2AF homologs to contribute to the regulation of alternative splicing.
Received for publication, February 7, 2008 , and in revised form, May 5, 2008.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1-4.
1 To whom correspondence should be addressed: Institut de Recherches Cliniques de Montréal, 110 Ave. des Pins Ouest, Montréal, Quebec H2W 1R7, Canada. Tel.: 514-987 5501; Fax: 514-987 5679; E-mail: Tarik.Moroy{at}ircm.qc.ca.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |